Scientists developed a custom targeted cell free DNA (cfDNA) sequencing assay, named AR-ctDETECT, to detect circulating tumor DNA in limiting plasma cfDNA available from metastatic CRPC patients in the Alliance A031201 randomized Phase III trial of enzalutamide with or without abiraterone.
[Nature Communications]
